Publication:
The electroencephalography protocol for the Accelerating Medicines Partnership® Schizophrenia Program: Reliability and stability of measures

Simple item page
dc.contributor.authorMathalon, Daniel H.
dc.contributor.authorNicholas, Spero
dc.contributor.authorRoach, Brian J.
dc.contributor.authorBillah, Tashrif
dc.contributor.authorLavoie, Suzie
dc.contributor.authorWhitford, Thomas
dc.contributor.authorHamilton, Holly K.
dc.contributor.authorAddamo, Lauren
dc.contributor.authorAnohkin, Andrey
dc.contributor.authorBekinschtein, Tristan
dc.contributor.authorBelger, Aysenil
dc.contributor.authorBuccilli, Kate
dc.contributor.authorCahill, John
dc.contributor.authorCarrión, Ricardo E.
dc.contributor.authorDamiani, Stefano
dc.contributor.authorDzafic, Ilvana
dc.contributor.authorEbdrup, Bjørn H.
dc.contributor.authorIzyurov, Igor
dc.contributor.authorJarcho, Johanna
dc.contributor.authorJenni, Raoul
dc.contributor.authorJo, Anna
dc.contributor.authorKerins, Sarah
dc.contributor.authorLee, Clarice
dc.contributor.authorMartin, Elizabeth A.
dc.contributor.authorMayol-Troncoso, Rocio
dc.contributor.authorNiznikiewicz, Margaret A.
dc.contributor.authorParvaz, Muhammad
dc.contributor.authorPogarell, Oliver
dc.contributor.authorPrieto-Montalvo, Julio
dc.contributor.authorRabin, Rachel
dc.contributor.authorRoalf, David R.
dc.contributor.authorRogers, Jack
dc.contributor.authorSalisbury, Dean F.
dc.contributor.authorShaik, Riaz
dc.contributor.authorShankman, Stewart
dc.contributor.authorStevens, Michael C.
dc.contributor.authorSuen, Yi Nam
dc.contributor.authorSwann, Nicole C.
dc.contributor.authorTang, Xiaochen
dc.contributor.authorCastillo-Passi, Rolando I.
dc.date.accessioned2026-07-22T16:07:22Z
dc.date.available2026-07-22T16:07:22Z
dc.date.issued2025
dc.descriptionJudy L. Thompson, Ivy Tso, Julian Wenzel, Juan Helen Zhou, Jean Addington, Luis Alameda, Celso Arango, Nicholas J. K. Breitborde, Matthew R. Broome, Kristin S. Cadenhead, Monica E. Calkins, Eric Yu Hai Chen, Jimmy Choi, Philippe Conus, Cheryl M. Corcoran, Barbara A. Cornblatt, Covadonga M. Diaz-Caneja, Lauren M. Ellman, Paolo Fusar-Poli, Pablo A. Gaspar, Carla Gerber, Louise Birkedal Glenthøj, Leslie E. Horton, Christy Lai Ming Hui, Joseph Kambeitz, Lana Kambeitz-Ilankovic, Matcheri S. Keshavan, Minah Kim, Sung-Wan Kim, Nikolaos Koutsouleris, Jun Soo Kwon, Kerstin Langbein, Daniel Mamah, Vijay A. Mittal, Merete Nordentoft, Godfrey D. Pearlson, Jesus Perez, Diana O. Perkins, Albert R. Powers, Fred W. Sabb, Jason Schiffman, Jai L. Shah, Steven M. Silverstein, Stefan Smesny, William S. Stone, Gregory P. Strauss, Rachel Upthegrove, Swapna K. Verma, Jijun Wang, Daniel H. Wolf, Tianhong Zhang, Sylvain Bouix, Ofer Pasternak, Kang-Ik K. Cho, Michael J. Coleman, Dominic Dwyer, Angela Nunez, Zailyn Tamayo, Stephen J. Wood, Rene S. Kahn, John M. Kane, Patrick D. McGorry, Carrie E. Bearden, Barnaby Nelson, Scott W. Woods, Martha E. Shenton, Accelerating Medicines Partnership® Schizophrenia Program and Gregory A. Light.
dc.description.abstractIndividuals at clinical high risk for psychosis (CHR) have variable clinical outcomes and low conversion rates, limiting development of novel and personalized treatments. Moreover, given risks of antipsychotic drugs, safer effective medications for CHR individuals are needed. The Accelerating Medicines Partnership® Schizophrenia (AMP® SCZ) Program was launched to address this need. Based on past CHR and schizophrenia studies, AMP SCZ assessed electroencephalography (EEG)-based event-related potential (ERP), eventrelated oscillation (ERO), and resting EEG power spectral density (PSD) measures, including mismatch negativity (MMN), auditory and visual P300 to target (P3b) and novel (P3a) stimuli, 40-Hz auditory steady state response, and resting EEG PSD for traditional frequency bands (eyes open/closed). Here, in an interim analysis of AMP SCZ EEG measures, we assess test-retest reliability and stability over sessions (baseline, month-2 follow-up) in CHR (n=654) and community control (CON; n=87) participants. Reliability was calculated as Generalizability (G)-coefficients, and changes over session were assessed with paired t-tests. G-coefficients were generally good to excellent in both groups (CHR: mean =0.72, range=0.49–0.85; CON: mean=0.71, range=0.44–0.89). Measure magnitudes significantly (p < 0.001) decreased over session (MMN, auditory and visual target P3b, visual novel P3a, 40-Hz ASSR) and/or over runs within sessions (MMN, auditory/visual novel P3a and target P3b), consistent with habituation effects. Despite these small systematic habituation effects, test-retest reliabilities of the AMP SCZ EEG-based measures are sufficiently strong to support their use in CHR studies as potential predictors of clinical outcomes, markers of illness progression, and/or target engagement or secondary outcome measures in controlled clinical trials. Watch Dr Daniel H. Mathalon discuss their work and this article: https://vimeo.com/1066564687.
dc.description.versionVersión publicada
dc.format.extent18 p.
dc.identifier.citationMathalon, D. H., Nicholas, S., Roach, B. J., Billah, T., Lavoie, S., Whitford, T., Hamilton, H. K., Addamo, L., Anohkin, A., Bekinschtein, T., Belger, A., Buccilli, K., Cahill, J., Carrión, R. E., Damiani, S., Dzafic, I., Ebdrup, B. H., Izyurov, I., Jarcho, J., … Light, G. A. (2025). The electroencephalography protocol for the Accelerating Medicines Partnership® Schizophrenia Program: Reliability and stability of measures. Schizophrenia, 11(1), 85. https://doi.org/10.1038/s41537-025-00622-0
dc.identifier.doihttps://doi.org/10.1038/s41537-025-00622-0
dc.identifier.urihttps://hdl.handle.net/11447/10893
dc.language.isoen
dc.rightsAtribución-NoComercial-CompartirIgual 3.0 Chile (CC BY-NC-SA 3.0 CL)
dc.rights.urihttp://creativecommons.org/licenses/by-nc-sa/3.0/cl/
dc.titleThe electroencephalography protocol for the Accelerating Medicines Partnership® Schizophrenia Program: Reliability and stability of measures
dc.typeArticle
dcterms.accessRightsAcceso abierto
dcterms.sourceSchizophrenia
dspace.entity.typePublication

Files

Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
The electroencephalography protocol for the Accelerating Medicines Partnership® Schizophrenia Program: Reliability and stability of measures.pdf
Size:
8.11 MB
Format:
Adobe Portable Document Format
Download
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
347 B
Format:
Item-specific license agreed upon to submission
Description:
Download

Collections

Artículos Psicología

Implementado por OpenGeek Services